E for L Aim Public Company (EFORL) Fair Value & Analysis
Healthcare · TH · Market cap 520M THB
Fair value as of: Jun 26, 2026
Analysis
E for L Aim Public Company (EFORL) currently trades at 0.1300 THB, while our model-based Fair Value estimate is 0.1900 THB — implying the stock looks roughly 46.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
E for L Aim Public Company Limited, together with its subsidiaries, engages in the distribution of medical devices and equipment in Thailand, the United States, Europe, and Asia. The company offers medical devices, including patient and central monitor systems, defibrillator, automated external defibrillator, electrocardiographs, electroencephalogram, PSG system, and accessories and consumables, as well as ICU, transport, and MRI ventilators, anesthesia delivery system, incubator and radiant warmer, phototherapy, spirometer, pulmonary function lab, and cardiopulmonary exercise testing devices. It also provides handheld and ultrasound scanners, high flow oxygen therapy, ceiling pendant, hemodialysis machine, continuous renal replacement therapy, ozone hybrid, patients and medical devices tracking system, MRI infusion and monitor systems, MRI ferrous metal detector, video laryngoscope, hydrogen peroxide plasma sterilizing, and picture archiving and communication devices, as well as cl…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is E for L Aim Public Company (EFORL) undervalued?
What is the fair value of EFORL?
What is the quality score of EFORL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.